scholarly journals Aberrant methylation ofTMS1 in small cell, non small cell lung cancer and breast cancer

2003 ◽  
Vol 106 (2) ◽  
pp. 198-204 ◽  
Author(s):  
Arvind Virmani ◽  
Asha Rathi ◽  
Kenji Sugio ◽  
Ubaradka G. Sathyanarayana ◽  
Shinichi Toyooka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

scholarly journals Aberrant methylation modifications reflect specific drug responses in small cell lung cancer

Genomics ◽  
2021 ◽  
Vol 113 (3) ◽  
pp. 1114-1126
Author(s):  
Peixin Chen ◽  
Haoyue Guo ◽  
Yu Liu ◽  
Bin Chen ◽  
Sha Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Specific Drug ◽  
Small Cell Lung ◽  
Drug Responses

scholarly journals 397 A phase I/II trial of intracerebroventricular 177Lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A429-A429
Author(s):  
Elena Pentsova ◽  
Maria Düring ◽  
Charlotte Lybek Lind ◽  
John Rømer Nielsen
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Solid Tumors ◽  
Cell Lung Cancer ◽  
Leptomeningeal Metastasis ◽  
Primary Objective ◽  
Small Cell ◽  
Lobular Breast Cancer ◽  
Small Cell Lung

BackgroundLeptomeningeal metastasis (LM) from solid tumors may be diagnosed in approximately 10% of patients with metastatic cancer and can occur with virtually all malignant tumors. Median overall survival (OS) is poor and limited to a few months with LM-directed treatment, including available targeted therapy, immunotherapy and radiation therapy. Omburtamab specifically binds to B7-H3 (CD276), a transmembrane glycoprotein of the immunoglobulin superfamily. The limited expression of B7-H3 on normal cells, including normal brain, combined with the broad expression in various types of solid tumors, makes B7-H3 a target for radioimmunotherapy of LM from solid tumors. In this first-in-human trial the safety and efficacy of intracerebroventricular administration of radiolabeled omburtamab, 177Lu-DTPA-omburtamab, will be evaluated in patients with LM from ductal or lobular breast cancer, non-small cell lung cancer, or melanoma.MethodsThis is an open-label phase I/II study. Part 1 is a dose-escalation phase to be conducted at ~4 sites (US/Europe) with a primary objective of identifying the maximum tolerated dose and/or recommended phase II dose for Part 2 (RP2D). It will follow a 3+3 design with pts receiving up to five 5-week cycles of 177Lu-DTPA-omburtamab. Part 2 is a cohort-expansion phase at ~9 sites (US/Europe) in which a maximum of 48 patients in 3 cohorts (ductal or lobular breast cancer [cohort A], non-small cell lung cancer [cohort B], and melanoma [cohort C]) with up to 16 patients in each will receive up to five 5 week cycles of treatment with intracerebroventricular 177Lu DTPA omburtamab at the RP2D determined in Part 1. The primary objective of Part 2 is to establish the safety of repeat doses of 177Lu-omburtamab. Additional objectives of Parts 1/2 include the evaluation of absorbed radiation doses, PK profile, investigator-assessed response, duration of response, progression-free survival, and OS. Key inclusion criteria include diagnosis of either ductal or lobular breast cancer, non-small cell lung cancer, or malignant melanoma and diagnosis of recurrent or refractory LM; prior standard of care treatment of leptomeningeal disease; acceptable hematological, liver and kidney status; and a life expectancy of >2 months. The study has been approved by each institution’s ethics board, and patients provided informed consent before taking part.Trial RegistrationNCT04315246Ethics ApprovalThe study has been approved by each institution’s ethics board, and patients provided informed consent before taking part.

Abstract LB-A05: Profiling cell free DNA in breast cancer and non-small cell lung cancer using broad NGS assessment

2015 ◽  
Author(s):  
Nadia Solovieff ◽  
Matt Hims ◽  
Rebecca Leary ◽  
Derek Chiang ◽  
Caroline Germa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Free Dna ◽  
Free Dna

Aberrant methylation of FBN2 in human non-small cell lung cancer

Lung Cancer ◽  
2005 ◽  
Vol 50 (1) ◽  
pp. 43-49 ◽  
Author(s):  
Hong Chen ◽  
Makoto Suzuki ◽  
Yohko Nakamura ◽  
Miki Ohira ◽  
Soichiro Ando ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

Suramin in Non-small Cell Lung Cancer and Advanced Breast Cancer: Two Parallel Phase II Studies

1997 ◽  
Vol 36 (2) ◽  
pp. 171-174 ◽  
Author(s):  
Mansoor R. Mirza ◽  
Erik Jakobsen ◽  
Per Pfeiffer ◽  
Bente Lindebjerg-Clasen ◽  
Jonas Bergh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Advanced Breast ◽  
Small Cell Lung ◽  
Phase Ii Studies

Temozolomide therapy for patients with non-small cell lung cancer, breast cancer, or melanoma brain metastases.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e12539-e12539
Author(s):  
D. R. Naskhletashvili ◽  
V. A. Gorbunova ◽  
M. B. Bychkov ◽  
G. E. Chmutin ◽  
V. B. Karahan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast ◽  
Melanoma Brain Metastases
Sign in / Sign up

Export Citation Format

Share Document